Stake logo


Revance Therapeutics Inc

About RVNC

Revance Therapeutics, Inc. is a commercial stage biotechnology company. The Company is focused on advanced aesthetic and therapeutic offerings, including neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a purified botulinum toxin that does not contain human or animal-based components. The Company is also evaluating additional aesthetic and therapeutic indications for DaxibotulinumtoxinA for Injection including the full upper face, which includes glabellar lines, forehead lines and crow’s feet, and adult upper limb spasticity. It offers products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and OPUL. The RHA Collection of dermal fillers is a dermal filler for the correction of dynamic facial wrinkles and folds. OPUL’s product offering includes the point-of-sale platform, software and hardware terminal.

Buy US stocks in Australia starting with RVNC. Open an account and start investing today!

Market Capitalisation


Price-earnings ratio


Dividend yield




High today


Low today


Open price


52-week high


52-week low



One share of Revance Therapeutics Inc is valued at $34.42.

The ticker symbol for Revance Therapeutics Inc is RVNC.

To buy RVNC stocks in Australia you'll need to open an account with a broker like Stake.
To do so follow these steps:
  1. Sign up in minutes, all you need is some I.D.
  2. Choose Stake Wall St
  3. Deposit directly into your Stake wallet and you're ready to invest in RVNC

As of 07/02/2023 Revance Therapeutics Inc has a market cap of $2.8B.

The Revance Therapeutics Inc 52-week high stock price is $35.99.

The Revance Therapeutics Inc 52-week low stock price is $11.27.

Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.